Smart Phone App Intervention In Young Adults With Cancer

Sponsor
Dana-Farber Cancer Institute (Other)
Overall Status
Completed
CT.gov ID
NCT04119869
Collaborator
(none)
25
1
1
7.6
3.3

Study Details

Study Description

Brief Summary

This research study aims to explore the feasibility and acceptability of a smartphone application intervention, called iaya, among young adults with cancer.

Condition or Disease Intervention/Treatment Phase
  • Other: iaya
N/A

Detailed Description

The iaya app was developed by clinicians from the Young Adult Program at the Dana-Farber Cancer Institute. The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.

The investigators are conducting this study to see if the iaya app, specifically developed for young adults with cancer, is practical, to determine patient satisfaction with the iaya app, and to test study procedures.

Study Design

Study Type:
Interventional
Actual Enrollment :
25 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Feasibility and Acceptability of a Smart Phone Application Intervention to Enhance Coping for Young Adults With Cancer
Actual Study Start Date :
Nov 11, 2019
Actual Primary Completion Date :
Jun 29, 2020
Actual Study Completion Date :
Jun 29, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: iaya Smart Phone Application

Pre-study evaluation Access to the smartphone intervention over the course of 12 weeks Post-study evaluation and interview

Other: iaya
The iaya app is a smartphone application intervention that -through a variety of approaches, such as exercises aimed at identifying and changing thoughts and behaviors, imagery, and relaxation- seeks to enhance coping with the emotional impact of cancer.

Outcome Measures

Primary Outcome Measures

  1. Number of participants who log in at least 10 times and open at least 3 coping skills exercises [12 weeks]

    Feasibility of iaya will be determined by calculating the percent of participants assigned to the iaya app who log in at least 10 times. Percent of participants assigned to the iaya app will open at least 3 coping skills exercises will also be considered as a component of feasibility.

  2. Mean score on app usability questionnaire [12 weeks]

    Acceptability will be assessed with the 6-item app usability questionnaire rated on a Likert scale (0=strong disagree to 5=strongly agree). Items will prompt participants to rate the extend to which they would use this app frequently, found the app to be easy to use, well organized, learn how to use the app quickly, felt confident using the app, and if they found the app interactive. Scores can range from 0-30. Higher scores indicate higher perception of usability.

Secondary Outcome Measures

  1. Change in coping scores on the Cancer Behavior Inventory Brief Form [12 weeks]

    We will pilot the 12-item Cancer Behavior Inventory Brief Form (CBI-B) for future efficacy studies. The CBI-B measures self-efficacy for coping with cancer. Items are scored between 1 (not at all confident) to 9 (totally confident). Higher scores indicate a higher level of self-efficacy for coping with cancer. among young adults with cancer who had access to the iaya app for future efficacy studies.

  2. Change in self-efficacy scores on the PROMIS Self-Efficacy for Managing Emotions Scale [12 weeks]

    We will pilot the 8-item PROMIS Self-Efficacy for Managing Emotions (PROMIS SEMEM) for future efficacy studies. The PROMIS SEMEM will be used to measure confidence to manage or control symptoms of anxiety, depression, helplessness, discouragement, frustration, disappointment, and anger. Items are scored on a scale from 1 (not at all confident) to 5 (very confident). Higher scores indicate a higher level of self-efficacy for managing emotions.

  3. Change in emotional support on the PROMIS Emotional Support Scale [12 weeks]

    We will pilot the 12-item PROMIS Emotional Support (PROMIS ES) for future efficacy studies. The PROMIS ES measures perceived feelings of being cared for and valued as a person. Items are scores on a scale from 1 (never) to 5 (always). Higher scores indicate higher levels of perceived emotional support.

  4. Change in quality of life on the Functional Assessment of Cancer Therapy-General Scale [12 weeks]

    We will pilot the 27-item Functional Assessment of Cancer Therapy-General (FACT-G) for future efficacy studies. The FACT-G consists of four sub scales: physical, emotional, social/family, and functional well-being. Items are scores between 0 (not at all) and 4 (very much). Higher scores indicate a higher level of quality of life.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 39 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged 18-39 years

  • Able to speak/read English

  • Have a smart phone

  • Receiving cancer treatment

  • Active cancer care from an oncologist at Dana-Farber Cancer Institute

Exclusion Criteria:
  • Neurological/cognitive condition interfering with the ability to understand and adhere to study procedures

  • Adults unable to consent

  • Individuals who are not yet adults (infants, children, teenagers)

  • Pregnant women

  • Prisoners

Contacts and Locations

Locations

Site City State Country Postal Code
1 Dana-Farber Cancer Institute Boston Massachusetts United States 02215

Sponsors and Collaborators

  • Dana-Farber Cancer Institute

Investigators

  • Principal Investigator: Hanneke Poort, PhD, Dana-Farber Cancer Institute

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Hanneke Poort PhD, Principal Investigator, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT04119869
Other Study ID Numbers:
  • 19-333
First Posted:
Oct 9, 2019
Last Update Posted:
Dec 8, 2020
Last Verified:
Dec 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hanneke Poort PhD, Principal Investigator, Dana-Farber Cancer Institute

Study Results

No Results Posted as of Dec 8, 2020